Ann: Investor Presentation, page-16

Data from the Investor Presentation & this is what is causing all the excitement. Treatment then rechallenge with the tumour:




And then if you want to look at potential collaborations/partnerships in solid tumours & the cancer cell lines addressed by CF-33 (>60 as stated by LC in the interview), that these CAR T treatments are (not yet) able to treat (can see the effect on tumour above in the graphs). Pre-clinical yes, but shortly we will see CF33 in the clinic in Ph1.

Apologies for rambling on, but this puts into perspective the lastest interview LC did (posted by @Oxxa on the media thread) & had read through all of this before listening. Just amazing!! GLTAH